Publisher's Synopsis
Edited by experts from one of the world's largest leukemia centers, this book provides information on the biology of the variety of leukemic disorders, up-to-date diagnostic testing and many new developments in therapy. Chapters covering new treatments present an outlook for the future and explain the rationale for ongoing clinical trials.
Topics include:
- Targeted therapy, e.g. tyrosine kinase inhibitors (Flt3, Aurora kinase inhibitors, kit inhibitors, BCR-ABL inhibitors)
- Ras inhibitors
- Epigenetic therapy (hypomethylaters and histone deacetylase inhibitors)
- Lenalidomide analogs
- New chemotherapy drugs, e.g. clofarabine, cloretazine, sapacitabine, forodesine
- Combinations of chemotherapy with kinase inhibitors (e.g. ALL induction protocols in combination with dasatinib or imatinib)
- New monoclonal antibodies (lumiliximab, humaxCD20, anti-CD40)
- Thrombopoietic agents
Leukemias: Principles and Practice of Therapy
- Includes practical information to guide you in challenging situations, such as treatment of elderly patients, pregnancy, relapsed and refractory disease
- Incorporates chapters on supportive care and pharmacologic information about the most frequently used drugs in this area
